Mesoblast Management

Management Kriterienprüfungen 4/4

Mesoblast's CEO ist Silviu Itescu , ernannt in Jan 2011, hat eine Amtszeit von 13.42 Jahren. Die jährliche Gesamtvergütung beträgt $1.11M , bestehend aus 60.6% Gehalt und 39.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.92% der Aktien des Unternehmens, im Wert von A$90.01M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.7 Jahre bzw. 6 Jahre.

Wichtige Informationen

Silviu Itescu

Geschäftsführender

US$1.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	60.6%
Amtszeit als Geschäftsführer	13.4yrs
Eigentum des Geschäftsführers	6.9%
Durchschnittliche Amtszeit des Managements	4.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Silviu Itescu im Vergleich zu den Einnahmen von Mesoblast verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	n/a	n/a	-US$73m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	US$1m	US$673k	-US$82m
Mar 31 2023	n/a	n/a	-US$81m
Dec 31 2022	n/a	n/a	-US$84m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	US$1m	US$697k	-US$91m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	n/a	n/a	-US$97m
Sep 30 2021	n/a	n/a	-US$97m
Jun 30 2021	US$2m	US$757k	-US$99m
Mar 31 2021	n/a	n/a	-US$109m
Dec 31 2020	n/a	n/a	-US$98m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	US$2m	US$697k	-US$78m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	n/a	n/a	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	US$1m	US$709k	-US$90m
Mar 31 2019	n/a	n/a	-US$90m
Dec 31 2018	n/a	n/a	-US$86m
Sep 30 2018	n/a	n/a	-US$48m
Jun 30 2018	US$2m	US$748k	-US$35m
Mar 31 2018	n/a	n/a	-US$42m
Dec 31 2017	n/a	n/a	-US$30m
Sep 30 2017	n/a	n/a	-US$64m
Jun 30 2017	US$1m	US$776k	-US$77m

Vergütung im Vergleich zum Markt: SilviuDie Gesamtvergütung ($USD1.11M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Australian ($USD1.04M).

Entschädigung vs. Einkommen: SilviuDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Silviu Itescu (67 yo)

13.4yrs

Amtszeit

US$1,109,634

Vergütung

Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesobla...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Silviu Itescu	Founder	13.4yrs	US$1.11m	6.92% $ 77.4m
Eric Rose	Chief Medical Officer & Executive Director	2.3yrs	US$1.02m	0.036% $ 403.4k
Andrew Chaponnel	Interim Chief Finance Officer	2.8yrs	keine Daten	keine Daten
Peter Howard	General Counsel & Corporate Executive	12.9yrs	keine Daten	keine Daten
Roger Brown	Head of Spinal Orthopedic Disorders	8.7yrs	keine Daten	keine Daten
Michael Schuster	Head of Pharma Partnering	no data	keine Daten	keine Daten
Geraldine Storton	Head of Regulatory Affairs & Quality Management	no data	keine Daten	keine Daten
Justin Horst	Head of Manufacturing	no data	keine Daten	keine Daten
Niva Sivakumar	Joint Company Secretary	4.7yrs	keine Daten	keine Daten
Paul Hughes	Joint Company Secretary	2.2yrs	keine Daten	keine Daten
Kenneth Borow	Executive	no data	keine Daten	keine Daten

4.7yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrenes Management: MSBDas Führungsteam des Unternehmens gilt als erfahren (4.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Silviu Itescu	Founder	17yrs	US$1.11m	6.92% $ 77.4m
Eric Rose	Chief Medical Officer & Executive Director	11.2yrs	US$1.02m	0.036% $ 403.4k
Philip Facchina	Independent Non-Executive Director	3.3yrs	US$135.62k	0.022% $ 241.5k
Joseph Swedish	Independent Non-Executive Director	6yrs	US$247.95k	0.040% $ 450.3k
William A. Burns	Independent Non-Executive Vice Chairman	10.3yrs	US$132.70k	0.0093% $ 104.1k
Henry Krum	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Joseph Lane	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Robert Graham	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Jane Bell	Independent Non-Executive Chairman	1.8yrs	US$139.29k	0.048% $ 532.6k
Richard Gilbert	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Stephen Graves	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Philip Krause	Non Executive Director	2.3yrs	US$138.33k	0.034% $ 379.7k

6.0yrs

Durchschnittliche Betriebszugehörigkeit

72yo

Durchschnittliches Alter

Erfahrener Vorstand: MSBDie Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).

Mesoblast Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Independent Non-Executive Director recently bought AU$200k worth of stock

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Insider recently bought AU$111k worth of stock

Recent updates

Independent Non-Executive Director recently bought AU$200k worth of stock

No longer forecast to breakeven

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

New minor risk - Share price stability

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

New major risk - Shareholder dilution

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

No longer forecast to breakeven

First half 2024 earnings released: US$0.038 loss per share (vs US$0.057 loss in 1H 2023)

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.14 loss in FY 2022)

New major risk - Share price stability

Forecast breakeven date pushed back to 2026

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Third quarter 2023 earnings released: US$0.025 loss per share (vs US$0.033 loss in 3Q 2022)

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.033 loss per share (vs US$0.04 loss in 2Q 2022)

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.035 loss in 1Q 2022)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Insider recently bought AU$111k worth of stock

Full year 2022 earnings released: US$0.14 loss per share (vs US$0.16 loss in FY 2021)

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Forecast to breakeven in 2025

Mesoblast Limited Provides Litigation Update

Third quarter 2022 earnings released: US$0.033 loss per share (vs US$0.044 loss in 3Q 2021)

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Forecast to breakeven in 2024

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

No longer forecast to breakeven

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Insufficient new directors

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.15 loss per share (vs US$0.15 loss in FY 2020)

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.028 loss in 3Q 2020)

Forecast to breakeven in 2024

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Revenue beats expectations

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.046 loss in 2Q 2020)

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

New 90-day low: AU$2.43